资源类型：
期刊/会议
收录情况：
◇ SCIE
◇ CPCI(ISTP)
文章类型：
会议摘要
作者：
Gao, M.[1,2,3]
*
;
Chi, Y.[4]
;
Tang, P.[5]
;
Zheng, X.[1,2,3]
;
Xu, Z.[6]
;
Li, D.[1,2,3]
;
Chen, X.[7]
;
Ge, M.[8,9,10,11,12]
;
Zhang, Y.[13]
;
Guo, Z.[14]
;
Wang, J.[15]
;
Chen, J.[16]
;
Zhang, J.[17]
;
Cheng, Y.[18]
;
Li, Z.[19]
;
Liu, H.[20]
;
Qin, J.[21,22]
;
Zhu, J.[23]
;
Cheng, R.[24]
;
机构：
[1]Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China
[2]Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3]Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[4]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[5]Chinese Acad Med Sci & Peking Union Med Coll, Dept VIP, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[6]Chinese Acad Med Sci & Peking Union Med Coll, Head & Neck Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[7]Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China
首都医科大学附属同仁医院
[8]Chinese Acad Sci, Inst Canc & Basic Med ICBM, Head & Neck Surg, Hangzhou, Peoples R China
[9]Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[10]Zhejiang Canc Hosp, Hangzhou, Peoples R China
[11]Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China
[12]Hangzhou Med Coll, Peoples Hosp, Hangzhou, Peoples R China
[13]Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Head & Neck Surg Dept,Jiangsu Canc Hosp, Nanjing, Peoples R China
[14]Sun Yat Sen Univ, Ctr Canc, Head & Neck Surg, Guangzhou, Peoples R China
[15]Gansu Prov Canc Hosp, Head & Neck Surg, Lanzhou, Peoples R China
[16]Hunan Canc Hosp, Head & Neck Surg Dept 1, Changsha, Peoples R China
[17]Harbin Med Univ, Canc Hosp, Thyroid Surg Ward, Harbin, Peoples R China
[18]Jilin Canc Hosp, Dept Med Oncol, Changchun, Jilin, Peoples R China
[19]China Med Univ, Liaoning Tumor Hosp & Inst, Tumor Hosp, Dept Head & Neck Surg, Shenyang, Peoples R China
[20]Fujian Canc Hosp, Head & Neck Dept, Fuzhou, Peoples R China
[21]Zhengzhou Univ, Affiliated Canc Hosp, Thyroid & Head & Neck Surg, Zhengzhou, Peoples R China
河南省肿瘤医院
[22]Henan Canc Hosp, Zhengzhou, Peoples R China
河南省肿瘤医院
[23]Sichuan Univ, West China Hosp, Thyroid Surg, Chengdu, Peoples R China
四川大学华西医院
[24]Kunming Med Univ, Affiliated Hosp 1, Dept Thyroid Surg, Kunming, Yunnan, Peoples R China
昆明医科大学附属第一医院
ISSN：
0923-7534
WOS：
WOS:000573469102504
中科院(CAS)分区：
出版当年[2021]版：
大类
|
1 区
医学
小类
|
1 区
肿瘤学
最新[2023]版：
大类
|
1 区
医学
小类
|
1 区
肿瘤学
影响因子：
56.7
最新[2023版]
38.2
最新五年平均
32.976
出版当年[2020版]
22.846
出版当年五年平均
18.274
出版前一年[2019版]
51.769
出版后一年[2021版]
第一作者：
Gao, M.
第一作者机构：
[1]Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China
[2]Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3]Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
推荐引用方式(GB/T 7714)：
Gao M.,Chi Y.,Tang P.,et al.Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk[J].ANNALS OF ONCOLOGY.2020,31:S1088-S1088.doi:10.1016/j.annonc.2020.08.1408.
APA：
Gao, M.,Chi, Y.,Tang, P.,Zheng, X.,Xu, Z....&Cheng, R..(2020).Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk.ANNALS OF ONCOLOGY,31,
MLA：
Gao, M.,et al."Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk".ANNALS OF ONCOLOGY 31.(2020):S1088-S1088
医学